CN100358577C
(zh)
|
1999-05-07 |
2008-01-02 |
杰南技术公司 |
抗体在制备治疗哺乳动物自身免疫病的试剂中的用途
|
CA2441903C
(en)
*
|
2000-05-26 |
2012-07-31 |
National Research Council Of Canada |
Single-domain brain-targeting antibody fragments derived from llama antibodies
|
WO2001090190A2
(en)
*
|
2000-05-26 |
2001-11-29 |
National Research Council Of Canada |
Single-domain antigen-binding antibody fragments derived from llama antibodies
|
ES2368623T3
(es)
*
|
2000-12-13 |
2011-11-18 |
Bac Ip B.V. |
Matrices de proteína de dominios variables de inmunoglobulina de cadena pesada de camilidae.
|
US20030133939A1
(en)
*
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US7829084B2
(en)
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
US7754208B2
(en)
*
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US8163289B2
(en)
|
2001-03-09 |
2012-04-24 |
Iterative Therapeutics, Inc. |
Methods and compositions involving polymeric immunoglobulin fusion proteins
|
US7511121B2
(en)
|
2001-03-09 |
2009-03-31 |
Arnason Barry G W |
Polymeric immunoglobulin fusion proteins that target low-affinity Fcγreceptors
|
GB0110029D0
(en)
*
|
2001-04-24 |
2001-06-13 |
Grosveld Frank |
Transgenic animal
|
US20040058445A1
(en)
*
|
2001-04-26 |
2004-03-25 |
Ledbetter Jeffrey Alan |
Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
|
JP4213586B2
(ja)
*
|
2001-09-13 |
2009-01-21 |
株式会社抗体研究所 |
ラクダ抗体ライブラリーの作製方法
|
EP1439857B1
(en)
|
2001-10-12 |
2009-02-25 |
Schering Corporation |
USE OF BISPECIFIC ANTIBODIES BINDING TO THE ACTIVATING RECEPTOR FcEpsilonRI AND TO THE INHIBITING RECEPTOR OX2Ra (CD200Ra) TO REGULATE IMMUNE RESPONSES
|
JP2005289809A
(ja)
|
2001-10-24 |
2005-10-20 |
Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) |
突然変異重鎖抗体
|
US20030175272A1
(en)
*
|
2002-03-07 |
2003-09-18 |
Medcell Biologics, Inc. |
Re-activated T-cells for adoptive immunotherapy
|
US20030219436A1
(en)
*
|
2002-03-15 |
2003-11-27 |
Ledbetter Jeffrey A. |
Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
|
US20090217404A1
(en)
*
|
2002-09-27 |
2009-08-27 |
Lowe Scott W |
Cell-based RNA interference and related methods and compositions
|
US20090186839A1
(en)
*
|
2003-02-17 |
2009-07-23 |
Cold Spring Harbor Laboratory |
Model for studying the role of genes in chemoresistance
|
DK1599573T3
(da)
*
|
2003-02-17 |
2013-07-08 |
Cold Spring Harbor Lab |
Model til at studere genernes rolle i tumorresistens over for kemoterapi
|
TW200502391A
(en)
*
|
2003-05-08 |
2005-01-16 |
Xcyte Therapies Inc |
Generation and isolation of antigen-specific t cells
|
US7754209B2
(en)
|
2003-07-26 |
2010-07-13 |
Trubion Pharmaceuticals |
Binding constructs and methods for use thereof
|
JP4818917B2
(ja)
*
|
2003-08-08 |
2011-11-16 |
イミューノメディクス、インコーポレイテッド |
腫瘍および罹患細胞のアポトーシスを誘発するための二重特異性抗体
|
US20050118173A1
(en)
*
|
2003-09-22 |
2005-06-02 |
Xcyte Therapies, Inc. |
Compositions and methods to accelerate hematologic recovery
|
WO2005049085A1
(en)
*
|
2003-11-18 |
2005-06-02 |
Valeocyte Therapies Llc |
Use of soluble complexes to facilitate cell activation
|
WO2005075515A2
(en)
*
|
2004-02-06 |
2005-08-18 |
Unilever N.V. |
Immunoglobulins and method for their modification
|
US20070264277A1
(en)
|
2004-07-22 |
2007-11-15 |
Dirk Behrens |
Compositions and Methods of Use for Mgd-Csf in Disease Treatment
|
FR2879605B1
(fr)
|
2004-12-16 |
2008-10-17 |
Centre Nat Rech Scient Cnrse |
Production de formats d'anticorps et applications immunologiques de ces formats
|
US8137907B2
(en)
*
|
2005-01-03 |
2012-03-20 |
Cold Spring Harbor Laboratory |
Orthotopic and genetically tractable non-human animal model for liver cancer and the uses thereof
|
US8444973B2
(en)
*
|
2005-02-15 |
2013-05-21 |
Duke University |
Anti-CD19 antibodies and uses in B cell disorders
|
US20060280738A1
(en)
*
|
2005-06-08 |
2006-12-14 |
Tedder Thomas F |
Anti-CD19 antibody therapy for transplantation
|
PT1853718E
(pt)
*
|
2005-02-15 |
2015-11-12 |
Univ Duke |
Anticorpos anti-cd19 e usos em oncologia
|
WO2006121852A2
(en)
*
|
2005-05-05 |
2006-11-16 |
Duke University |
Anti-cd19 antibody therapy for autoimmune disease
|
CN103254309B
(zh)
|
2005-05-18 |
2017-09-26 |
埃博灵克斯股份有限公司 |
针对肿瘤坏死因子α的改进的纳米体TM
|
WO2006122825A2
(en)
|
2005-05-20 |
2006-11-23 |
Ablynx Nv |
Single domain vhh antibodies against von willebrand factor
|
DE102005023617A1
(de)
|
2005-05-21 |
2006-11-23 |
Aspre Ag |
Verfahren zum Mischen von Farben in einem Display
|
US20070044164A1
(en)
*
|
2005-05-31 |
2007-02-22 |
Cold Spring Harbor Laboratory |
Methods for producing microRNAs
|
DK2298815T3
(en)
|
2005-07-25 |
2015-06-15 |
Emergent Product Dev Seattle |
B-CELL REDUCTION USING CD37 SPECIFIC AND CD20 SPECIFIC BINDING MOLECULES
|
CA2654317A1
(en)
|
2006-06-12 |
2007-12-21 |
Trubion Pharmaceuticals, Inc. |
Single-chain multivalent binding proteins with effector function
|
PT2066349E
(pt)
|
2006-09-08 |
2012-07-02 |
Medimmune Llc |
Anticorpos anti-cd19 humanizados e respectiva utilização no tratamento de tumores, transplantação e doenças auto-imunes
|
AU2007336242B2
(en)
|
2006-12-19 |
2012-08-30 |
Ablynx N.V. |
Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
|
CA2672965C
(en)
|
2006-12-19 |
2018-02-06 |
Ablynx N.V. |
Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
|
EP2215123A1
(en)
|
2007-11-27 |
2010-08-11 |
Ablynx N.V. |
Immunoglobulin constructs
|
CA2720763A1
(en)
|
2008-04-07 |
2009-10-15 |
Ablynx Nv |
Amino acid sequences directed against the notch pathways and uses thereof
|
NZ621443A
(en)
|
2008-04-11 |
2015-09-25 |
Emergent Product Dev Seattle |
Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
|
WO2010010119A1
(en)
|
2008-07-22 |
2010-01-28 |
Ablynx Nv |
Amino acid sequences directed against multitarget scavenger receptors and polypeptides
|
EP3281955A1
(en)
|
2008-10-02 |
2018-02-14 |
Aptevo Research and Development LLC |
Cd86 antagonist multi-target binding proteins
|
CA2758191C
(en)
|
2009-04-10 |
2015-06-30 |
Ablynx N.V. |
Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
|
LT2438087T
(lt)
|
2009-06-05 |
2017-08-25 |
Ablynx N.V. |
Trivalenčiai nanokūno konstruktai prieš žmogaus respiratorinį sincitinį virusą (hrsv), skirti kvėpavimo takų infekcijų profilaktikai ir (arba) gydymui
|
EP2499488A1
(en)
*
|
2009-11-14 |
2012-09-19 |
Kuang-Yuh Chyu |
Immunomodulatory methods and systems for treatment and/or prevention of atherosclerosis
|
US9644022B2
(en)
|
2009-11-30 |
2017-05-09 |
Ablynx N.V. |
Amino acid sequences directed against human respiratory syncytial virus (HRSV) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
|
WO2011073180A1
(en)
|
2009-12-14 |
2011-06-23 |
Ablynx N.V. |
Single variable domain antibodies against ox40l, constructs and therapeutic use
|
WO2011083141A2
(en)
|
2010-01-08 |
2011-07-14 |
Ablynx Nv |
Method for generation of immunoglobulin sequences by using lipoprotein particles
|
US9120855B2
(en)
|
2010-02-10 |
2015-09-01 |
Novartis Ag |
Biologic compounds directed against death receptor 5
|
WO2011098518A2
(en)
|
2010-02-11 |
2011-08-18 |
Ablynx Nv |
Delivery of immunoglobulin variable domains and constructs thereof
|
US8937164B2
(en)
|
2010-03-26 |
2015-01-20 |
Ablynx N.V. |
Biological materials related to CXCR7
|
CN102906118B
(zh)
|
2010-05-20 |
2017-07-28 |
埃博灵克斯股份有限公司 |
与her3相关的生物材料
|
WO2011161263A1
(en)
|
2010-06-25 |
2011-12-29 |
Ablynx Nv |
Pharmaceutical compositions for cutaneous administration
|
EP2621953B1
(en)
|
2010-09-30 |
2017-04-05 |
Ablynx N.V. |
Biological materials related to c-met
|
PE20140772A1
(es)
|
2010-11-08 |
2014-07-03 |
Novartis Ag |
Polipeptidos que se enlazan a cxcr2
|
EP2673297A2
(en)
|
2011-02-11 |
2013-12-18 |
Zyngenia, Inc. |
Monovalent and multivalent multispecific complexes and uses thereof
|
CA2831415A1
(en)
|
2011-03-28 |
2012-10-04 |
Ablynx Nv |
Bispecific anti-cxcr7 immunoglobulin single variable domains
|
UA117218C2
(uk)
|
2011-05-05 |
2018-07-10 |
Мерк Патент Гмбх |
Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
|
AU2012273928A1
(en)
|
2011-06-23 |
2014-02-06 |
Ablynx Nv |
Immunoglobulin single variable domains directed against IgE
|
EP2753644A1
(en)
|
2011-09-09 |
2014-07-16 |
Universiteit Utrecht Holding B.V. |
Broadly neutralizing vhh against hiv-1
|
EP2747782B1
(en)
|
2011-09-23 |
2018-01-17 |
Ablynx NV |
Prolonged inhibition of interleukin-6 mediated signaling
|
AU2012316859A1
(en)
*
|
2011-09-29 |
2014-04-17 |
Apo-T B.V. |
Multi-specific binding molecules targeting aberrant cells
|
CA2850261C
(en)
|
2011-09-30 |
2021-04-20 |
Ablynx Nv |
C-met immunoglobulin single variable domains
|
US10112987B2
(en)
|
2012-01-09 |
2018-10-30 |
Icb International, Inc. |
Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
|
US10112988B2
(en)
|
2012-01-09 |
2018-10-30 |
Icb International, Inc. |
Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide
|
WO2013105856A1
(en)
|
2012-01-13 |
2013-07-18 |
Apo-T B.V. |
Aberrant cell-restricted immunoglobulins provided with a toxic moiety
|
US9328174B2
(en)
|
2012-05-09 |
2016-05-03 |
Novartis Ag |
Chemokine receptor binding polypeptides
|
WO2014087010A1
(en)
|
2012-12-07 |
2014-06-12 |
Ablynx N.V. |
IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
|
US20160075766A1
(en)
|
2013-05-21 |
2016-03-17 |
Roche Diagnostics Operations, Inc. |
Method for producing antibodies using ovine b-cells and uses thereof
|
PL3143042T3
(pl)
|
2014-05-16 |
2020-11-16 |
Ablynx N.V. |
Domeny zmienne immunoglobuliny
|
ES2944563T3
(es)
*
|
2014-05-19 |
2023-06-22 |
Hoffmann La Roche |
Procedimiento para producir anticuerpos usando linfocitos B ovinos y usos de los mismos
|
NL2013661B1
(en)
|
2014-10-21 |
2016-10-05 |
Ablynx Nv |
KV1.3 Binding immunoglobulins.
|
BR112016030740A2
(pt)
|
2014-07-01 |
2018-02-20 |
Pfizer Inc. |
diacorpos heterodiméricos biespecíficos e seus usos
|
KR20170093120A
(ko)
|
2014-10-10 |
2017-08-14 |
아블린쓰 엔.브이. |
Rsv 감염의 치료 방법
|
CN106999420B
(zh)
|
2014-10-10 |
2021-08-10 |
埃博灵克斯股份有限公司 |
用于呼吸***疾病的气溶胶疗法的吸入装置
|
PL3233910T3
(pl)
|
2014-12-19 |
2020-06-01 |
Ablynx N.V. |
Dimery nanociał połączone cysteiną
|
JP6929786B2
(ja)
|
2015-04-02 |
2021-09-01 |
アブリンクス エン.ヴェー. |
強力な抗hiv活性を有する二重特異性cxcr4−cd4ポリペプチド
|
ES2901273T3
(es)
|
2015-04-06 |
2022-03-21 |
Subdomain Llc |
Polipéptidos que contienen dominios de unión de novo y usos de los mismos
|
CN107847559B
(zh)
|
2015-05-13 |
2022-07-01 |
埃博灵克斯股份有限公司 |
基于cd3反应性的t细胞募集多肽
|
RS59376B1
(sr)
|
2015-05-13 |
2019-11-29 |
Ablynx Nv |
Polipeptidi koji regrutuju t-ćelije na bazi tcr-alfa/beta reaktivnosti
|
US11352426B2
(en)
|
2015-09-21 |
2022-06-07 |
Aptevo Research And Development Llc |
CD3 binding polypeptides
|
NO2768984T3
(pt)
|
2015-11-12 |
2018-06-09 |
|
|
PE20181956A1
(es)
|
2015-11-27 |
2018-12-17 |
Ablynx Nv |
Polipeptidos que inhiben cd40l
|
WO2017161051A1
(en)
*
|
2016-03-15 |
2017-09-21 |
Nexgenia, Inc. |
Cell-surface molecule binding stimuli-responsive polymer compositions and methods cross-reference to related applications
|
EP4273232A3
(en)
|
2016-03-30 |
2024-01-03 |
F. Hoffmann-La Roche AG |
B-cell cultivation method
|
WO2017191108A1
(en)
|
2016-05-02 |
2017-11-09 |
Ablynx Nv |
Treatment of rsv infection
|
WO2018007442A1
(en)
|
2016-07-06 |
2018-01-11 |
Ablynx N.V. |
Treatment of il-6r related diseases
|
WO2018029182A1
(en)
|
2016-08-08 |
2018-02-15 |
Ablynx N.V. |
Il-6r single variable domain antibodies for treatment of il-6r related diseases
|
EP3512880A1
(en)
|
2016-09-15 |
2019-07-24 |
Ablynx NV |
Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
|
MX2019005696A
(es)
|
2016-11-16 |
2019-08-14 |
Ablynx Nv |
Polipeptidos de reclutamiento de celulas t capaces de unir cd123 y tcr alfa/beta.
|
WO2018099968A1
(en)
|
2016-11-29 |
2018-06-07 |
Ablynx N.V. |
Treatment of infection by respiratory syncytial virus (rsv)
|
CN108264561B
(zh)
*
|
2016-12-30 |
2021-09-10 |
惠和生物技术(上海)有限公司 |
一种结合cd19、cd3和t细胞负共刺激分子的三功能分子及其应用
|
WO2018122147A1
(en)
|
2017-01-02 |
2018-07-05 |
F. Hoffmann-La Roche Ag |
B-cell cultivation method
|
US11891451B2
(en)
|
2017-05-11 |
2024-02-06 |
Vib Vzw |
Glycosylation of variable immunoglobulin domains
|
JP6978516B2
(ja)
|
2017-05-19 |
2021-12-08 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
胸腺細胞上清を産生するための方法
|
US11603401B2
(en)
|
2017-06-02 |
2023-03-14 |
Ablynx N.V. |
Aggrecan binding immunoglobulins
|
EP4272822A3
(en)
|
2017-06-02 |
2024-03-27 |
Merck Patent GmbH |
Adamts binding immunoglobulins
|
WO2018220235A1
(en)
|
2017-06-02 |
2018-12-06 |
Merck Patent Gmbh |
Mmp13 binding immunoglobulins
|
CA3064318A1
(en)
|
2017-06-02 |
2018-12-06 |
Merck Patent Gmbh |
Polypeptides binding adamts5, mmp13 and aggrecan
|
US11377482B2
(en)
|
2017-11-14 |
2022-07-05 |
Arcellx, Inc. |
D-domain containing polypeptides and uses thereof
|
JP7166342B2
(ja)
|
2017-11-30 |
2022-11-07 |
エフ.ホフマン-ラ ロシュ アーゲー |
B細胞培養法
|
EP3749690A1
(en)
|
2018-02-05 |
2020-12-16 |
Stichting VU |
Inverse agonistic anti-us28 antibodies
|
WO2019156566A1
(en)
|
2018-02-12 |
2019-08-15 |
Umc Utrecht Holding B.V. |
Bispecific molecules comprising gamma-delta tcr and t-cell or nk cell binding domain
|
CN111655296A
(zh)
|
2018-02-26 |
2020-09-11 |
埃博灵克斯股份有限公司 |
编码肽接头的经改良核苷酸序列
|
WO2019226050A2
(en)
|
2018-05-24 |
2019-11-28 |
Wageningen Universiteit |
Novel viral anti-infective reagents
|
EP3636657A1
(en)
|
2018-10-08 |
2020-04-15 |
Ablynx N.V. |
Chromatography-free antibody purification method
|
WO2020080941A1
(en)
|
2018-10-16 |
2020-04-23 |
Umc Utrecht Holding B.V. |
Anti- low-density lipoprotein receptor-related protein 5/6 antibodies
|
WO2020130838A2
(en)
|
2018-12-21 |
2020-06-25 |
Qvq Holding B.V. |
Antibodies for preventing or treating candidiasis
|
GB201901608D0
(en)
|
2019-02-06 |
2019-03-27 |
Vib Vzw |
Vaccine adjuvant conjugates
|
WO2020204714A1
(en)
|
2019-04-02 |
2020-10-08 |
Immunetune B.V. |
Immune-stimulatory compositions and use thereof
|
WO2020245663A1
(en)
|
2019-06-01 |
2020-12-10 |
Institut Pasteur |
Nanobody-based ns1 assay for the specific diagnosis of acute zika virus infection
|
US20220324947A1
(en)
|
2019-08-05 |
2022-10-13 |
Stichting Vu |
Identification and Elimination of HCMV-Infected Cells
|
WO2022036495A1
(en)
|
2020-08-17 |
2022-02-24 |
Utc Therapeutics Inc. |
Lymphocytes-antigen presenting cells co-stimulators and uses thereof
|
MX2023001962A
(es)
|
2020-08-19 |
2023-04-26 |
Xencor Inc |
Composiciones anti-cd28.
|
WO2022129637A1
(en)
|
2020-12-18 |
2022-06-23 |
Ablynx Nv |
T cell recruiting polypeptides based on tcr alpha/beta reactivity
|
CN117321076A
(zh)
|
2021-02-19 |
2023-12-29 |
美国卫生及公众服务部代表 |
中和SARS-CoV-2的单结构域抗体
|
EP4320229A1
(en)
|
2021-04-09 |
2024-02-14 |
Stichting Radboud Universiteit |
Off the shelf proximity biotinylation enzyme
|
WO2022258606A1
(en)
|
2021-06-07 |
2022-12-15 |
Gadeta B.V. |
Delta T-cell or Gamma T-cell receptor chains or parts thereof that mediate an anti-tumour or anti-infective response
|
WO2023014222A1
(en)
|
2021-08-03 |
2023-02-09 |
Wageningen Universiteit |
Argonaute-based nucleic acid detection system
|
WO2023227594A1
(en)
|
2022-05-24 |
2023-11-30 |
Gadeta Bv |
Novel deltat-cell receptor chains, gammat-cell receptor chains, or parts thereof
|
WO2023237541A1
(en)
|
2022-06-07 |
2023-12-14 |
Gadeta B.V. |
Delta t-cell or gamma t-cell receptor chains or parts thereof that mediate an anti-tumour or anti-infective response
|
WO2024013402A1
(en)
|
2022-07-15 |
2024-01-18 |
Gadeta B.V. |
Novel soluble gamma t-cell (or soluble delta t-cell) receptor chains (or soluble gammadelta t-cell receptors) or fragments thereof that mediate an anti-tumour or an anti-infective response
|
WO2024017915A1
(en)
|
2022-07-18 |
2024-01-25 |
Ablynx N.V. |
Cx3cr1-binding compounds, uses thereof and related methods
|
WO2024023271A1
(en)
|
2022-07-27 |
2024-02-01 |
Ablynx Nv |
Polypeptides binding to a specific epitope of the neonatal fc receptor
|
WO2024083843A1
(en)
|
2022-10-18 |
2024-04-25 |
Confo Therapeutics N.V. |
Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
|
WO2024096735A1
(en)
|
2022-10-31 |
2024-05-10 |
Stichting Amsterdam UMC |
Single domain anti-cd169 antibodies
|
WO2024101989A1
(en)
|
2022-11-08 |
2024-05-16 |
Stichting Amsterdam UMC |
Activation inducible antigen receptors for adoptive immunotherapy
|